To read the full story
Related Article
- Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
- Eisai Eyes Up to 280 Billion Yen Sales for Leqembi in FY2027: CEO
March 26, 2025
- Eisai Cuts Leqembi Sales Target as It Sees “Some Delays” in US Uptake
November 11, 2024
- Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai
April 25, 2024
- Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
- 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Broader Use of Blood Biomarkers Key to Maximizing Leqembi’s Value: Eisai Exec
October 18, 2023
- Eisai Sees Positive Shift in US Market for Leqembi after Full Approval: Exec
August 3, 2023
BUSINESS
- Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
- Chugai to Build New Research Building to Strengthen Process Development
July 25, 2025
- Chugai Drops Five Early-Stage Programs to Refocus Pipeline
July 25, 2025
- Pfizer Japan Recalls Syphilis Drug over Particulate Contamination
July 25, 2025
- Chugai Delivers Positive H1 Earnings on Innovative Drugs, Export Growth
July 25, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…